onr:"swepub:oai:DiVA.org:liu-29582"
Search: onr:"swepub:oai:DiVA.org:liu-29582" > Nine patients with ...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Eriksson, Per,1958-Linköpings universitet,Hälsouniversitetet,Reumatologi (author)
Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab
- Article/chapterEnglish2005
Publisher, publication year, extent ...
- Wiley,2005
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:liu-29582
- https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-29582URI
- https://doi.org/10.1111/j.1365-2796.2005.01494.xDOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Objectives. Rituximab (RIT) is a monoclonal anti-CD20 antibody, which depletes B-lymphocytes but not plasma cells. RIT is used for treatment of B-cell lymphomas, but has also shown beneficial effects in autoimmune diseases. In this case series RIT was used in anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis. Design. Case series with a structured follow-up of treated patients. Setting. Departments of Nephrology and Rheumatology of a university hospital. Subjects. Two women with myeloperoxidase-ANCA-positive microscopic polyangiitis and seven patients (five men and two women) with proteinase 3-ANCA-positive Wegener's granulomatosis. All patients were resistant to conventional therapy or had relapsed repeatedly after cessation of cyclophosphamide (Cyc). Interventions. The cases were treated with intravenous infusions of RIT once a week two times (three cases) or four times (six cases). To prevent formation of antibodies to RIT, mycophenolate mofetil (five patients), azathioprine (one patient), or a short course of Cyc (two patients) were added or allowed to continue. Mainoutcome measures. Remission at 6 months assessed with Birmingham vasculitis activity score. The cases were followed 6-24 months and relapse rate was also noted. Results. Eight of nine patients responded completely and one case responded partially. Pulmonary X-ray improved (four cases), progress of lower extremity gangrene stopped (one case), remission of neuropathy was stable (one patient), renal vasculitis went into remission (two cases), and severe musculoskeletal pain improved (one case). Minor relapse in the nose occurred in two cases. No adverse events or major infections were noted. Conclusion. RIT seems promising and safe in ANCA-positive vasculitis, and controlled studies should be conducted. © 2005 Blackwell Publishing Ltd.
Subject headings and genre
- anti-neutrophil cytoplasmic antibody
- rituximab
- therapy
- vasculitis
- MEDICINE
- MEDICIN
Added entries (persons, corporate bodies, meetings, titles ...)
- Linköpings universitetHälsouniversitetet (creator_code:org_t)
Related titles
- In:Journal of Internal Medicine: Wiley257:6, s. 540-5480954-68201365-2796
Internet link
Find in a library
- Journal of Internal Medicine (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Eriksson, Per, 1 ...
- Articles in the publication
- Journal of Inter ...
- By the university
- Linköping University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
